Welcome to our dedicated page for Kyowa Hakko news (Ticker: KYKOY), a resource for investors and traders seeking the latest updates and insights on Kyowa Hakko stock.
Kyowa Kirin develops and commercializes specialty pharmaceuticals for rare and debilitating diseases, with reported activity in hematology-oncology, rare bone disease, immunology, and other therapeutic areas. News for KYKOY centers on clinical and scientific updates, collaboration activity, medical-conference presentations, and research partnerships tied to the company’s global pharmaceutical business.
Recurring developments include rocatinlimab, an investigational OX40 receptor-targeting T-cell rebalancing therapy studied in the ROCKET Phase 3 program for moderate to severe atopic dermatitis; burosumab research in X-linked hypophosphatemia; and collaboration activity involving ziftomenib in acute leukemias. Coverage also reflects Kyowa Kirin’s industry-academic immunology research relationships and its commercial and development roles across Japan, North America, and global markets.
Kyowa Kirin announces successful Phase 2 study results for KHK4083, an anti-OX40 monoclonal antibody for treating moderate to severe atopic dermatitis. The trial met primary endpoints, showing significant improvement in the Eczema Area and Severity Index (EASI) at 16 weeks compared to placebo. Conducted in multiple countries with 274 patients, the study demonstrated ongoing efficacy beyond the initial 16 weeks. Common adverse events were reported, but no fatalities occurred. The company looks forward to sharing comprehensive results in future publications and presentations.
Kyowa Kirin and MEI Pharma announced that the first patient has been dosed in a pivotal Phase 2 study of zandelisib in Japan. This multicenter, open-label trial aims to evaluate zandelisib as a monotherapy for patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma (iNHL). In partnership, both companies seek to expand zandelisib's global development, with Kyowa Kirin holding exclusive rights outside the U.S. The study will include 60 patients, primarily measuring the objective response rate, and is expected to conclude by September 2024.